Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GHSR | Q92847 | 3/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.41 |
| ▸ | S100A10 | P60903 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4493472 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2AMEN1POLBNPSR1 | |
| SCHEMBL4504513 | 0.93 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2AMEN1POLBNPSR1 | |
| SCHEMBL4504518 | 0.93 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2AMEN1POLBNPSR1 | |
| SCHEMBL4503942 | 0.92 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2AMEN1POLBNPSR1 | |
| SCHEMBL4503948 | 0.92 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2AMEN1POLBNPSR1 | |
| SCHEMBL4488669 | 0.92 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2AMEN1POLBNPSR1 | |
| SCHEMBL4488674 | 0.92 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2AMEN1POLBNPSR1 | |
| SCHEMBL4480613 | 0.92 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2AMEN1POLBNPSR1 | |
| SCHEMBL4494162 | 0.92 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2AMEN1POLBCYP2D6 | |
| SCHEMBL4494155 | 0.92 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2AMEN1POLBCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1527046-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | SMN1; SMN2 4006/4885KMT2A 3530/4885MEN1 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.